Table 2 Patient characteristics and their clinical data
Characteristics | n = 229a |
|---|---|
Age, mean years ± SD (range) | 53 ± 7.16 (29–69) |
Gender, n (%) | |
 Female | 122 (53.3) |
 Male | 107 (46.7) |
Race, n (%) | |
 Malay | 220 (96.1) |
 Chinese | 7 (3.1) |
 Indian | 1 (0.4) |
 Others | 1 (0.4) |
Statin used, n (%) | |
 Atorvastatin (10–40 mg/day)b | 147 (64.2) |
 Simvastatin (10–40 mg/day)c | 60 (26.2) |
 Pravastatin (20 mg/day) | 16 (7.0) |
 Lovastatin (20 mg/day) | 6 (2.6) |
Diagnosed clinical manifestation, n (%) | |
 DM and HPT | 91 (39.7) |
 HPT | 85 (37.1) |
 HPL only | 29 (12.7) |
 DM and HPL | 24 (10.5) |
Concurrent treatment with statin, n (%) | |
 Anti-hypertensive drugs and diabetic medications | 88 (38.4) |
 Anti-hypertensive drugs only | 85 (37.1) |
 None | 35 (15.3) |
 Diabetic medications only | 21 (9.2) |
Antihypertensive drugs class, n (%) | |
 Combination of two or more anti-hypertensive drugs | 99 (57.2) |
 Calcium channel blockers only | 33 (19.1) |
 Angiotensin-converting enzyme (ACE) inhibitor only | 24 (13.9) |
 Angiotensin receptor blocker only | 10 (5.8) |
 Diuretic drugs only | 4 (2.3) |
 Beta-blockers only | 3 (1.7) |
Lipid level at the baseline, mean ± SD (mmol/L) | |
 TC (normal range < 5.2) | 5.72 ± 1.21 |
 HDL-c (normal range > 1.5) | 1.30 ± 0.47 |
 LDL-c (normal range < 2.6) | 3.72 ± 1.19 |
 TG (normal range < 1.7) | 1.65 ± 0.83 |